Jafron Biomedical Co Ltd
SZSE:300529
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.6
37.82
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Jafron Biomedical Co Ltd
Cash & Cash Equivalents
Jafron Biomedical Co Ltd
Cash & Cash Equivalents Peer Comparison
300760
688271
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Cash & Cash Equivalents
¥1.7B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
A
|
APT Medical Inc
SSE:688617
|
Cash & Cash Equivalents
¥1.3B
|
CAGR 3-Years
120%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Cash & Cash Equivalents
¥6.5B
|
CAGR 3-Years
28%
|
CAGR 5-Years
43%
|
CAGR 10-Years
35%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Cash & Cash Equivalents
¥20.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
L
|
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
|
Cash & Cash Equivalents
¥3.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Cash & Cash Equivalents
¥7.5B
|
CAGR 3-Years
34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Jafron Biomedical Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
1.7B
CNY
Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Cash & Cash Equivalents amounts to 1.7B CNY.
What is Jafron Biomedical Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
11%
Over the last year, the Cash & Cash Equivalents growth was -35%. The average annual Cash & Cash Equivalents growth rates for Jafron Biomedical Co Ltd have been -11% over the past three years , 11% over the past five years .
You don't have any saved screeners yet
